194 related articles for article (PubMed ID: 36604418)
1. Targeting tumor-stroma communication by blocking endothelin-1 receptors sensitizes high-grade serous ovarian cancer to PARP inhibition.
Tocci P; Roman C; Sestito R; Di Castro V; Sacconi A; Molineris I; Paolini F; Carosi M; Tonon G; Blandino G; Bagnato A
Cell Death Dis; 2023 Jan; 14(1):5. PubMed ID: 36604418
[TBL] [Abstract][Full Text] [Related]
2. Functional interaction between endothelin-1 and ZEB1/YAP signaling regulates cellular plasticity and metastasis in high-grade serous ovarian cancer.
Sestito R; Tocci P; Roman C; Di Castro V; Bagnato A
J Exp Clin Cancer Res; 2022 Apr; 41(1):157. PubMed ID: 35477522
[TBL] [Abstract][Full Text] [Related]
3. β-arrestin1/YAP/mutant p53 complexes orchestrate the endothelin A receptor signaling in high-grade serous ovarian cancer.
Tocci P; Cianfrocca R; Di Castro V; Rosanò L; Sacconi A; Donzelli S; Bonfiglio S; Bucci G; Vizza E; Ferrandina G; Scambia G; Tonon G; Blandino G; Bagnato A
Nat Commun; 2019 Jul; 10(1):3196. PubMed ID: 31324767
[TBL] [Abstract][Full Text] [Related]
4. CBL0137 impairs homologous recombination repair and sensitizes high-grade serous ovarian carcinoma to PARP inhibitors.
Lu X; He Y; Johnston RL; Nanayakarra D; Sankarasubramanian S; Lopez JA; Friedlander M; Kalimutho M; Hooper JD; Raninga PV; Khanna KK
J Exp Clin Cancer Res; 2022 Dec; 41(1):355. PubMed ID: 36539830
[TBL] [Abstract][Full Text] [Related]
5. Nuclear β-arrestin1 is a critical cofactor of hypoxia-inducible factor-1α signaling in endothelin-1-induced ovarian tumor progression.
Cianfrocca R; Tocci P; Rosanò L; Caprara V; Sestito R; Di Castro V; Bagnato A
Oncotarget; 2016 Apr; 7(14):17790-804. PubMed ID: 26909598
[TBL] [Abstract][Full Text] [Related]
6. Repurposing Ceritinib Induces DNA Damage and Enhances PARP Inhibitor Responses in High-Grade Serous Ovarian Carcinoma.
Kanakkanthara A; Hou X; Ekstrom TL; Zanfagnin V; Huehls AM; Kelly RL; Ding H; Larson MC; Vasmatzis G; Oberg AL; Kaufmann SH; Mansfield AS; Weroha SJ; Karnitz LM
Cancer Res; 2022 Jan; 82(2):307-319. PubMed ID: 34810199
[TBL] [Abstract][Full Text] [Related]
7. The disruption of the CCDC6 - PP4 axis induces a BRCAness like phenotype and sensitivity to PARP inhibitors in high-grade serous ovarian carcinoma.
Morra F; Merolla F; Damia G; Ricci F; Varricchio S; Ilardi G; Arenare L; Califano D; Napolitano V; Fruscio R; Melillo RM; Palazzo L; Celetti A
J Exp Clin Cancer Res; 2022 Aug; 41(1):245. PubMed ID: 35964058
[TBL] [Abstract][Full Text] [Related]
8. PARP inhibitor resistance and TP53 mutations in patients treated with olaparib for BRCA-mutated cancer: Four case reports.
Collot T; Niogret J; Carnet M; Chevrier S; Humblin E; Favier L; Bengrine-Lefevre L; Desmoulins I; Arnould L; Boidot R
Mol Med Rep; 2021 Jan; 23(1):. PubMed ID: 33236159
[TBL] [Abstract][Full Text] [Related]
9. Regulation of extracellular matrix degradation and metastatic spread by IQGAP1 through endothelin-1 receptor signalling in ovarian cancer.
Chellini L; Caprara V; Spadaro F; Sestito R; Bagnato A; Rosanò L
Matrix Biol; 2019 Aug; 81():17-33. PubMed ID: 30367951
[TBL] [Abstract][Full Text] [Related]
10. hMENA is a key regulator in endothelin-1/β-arrestin1-induced invadopodial function and metastatic process.
Di Modugno F; Caprara V; Chellini L; Tocci P; Spadaro F; Ferrandina G; Sacconi A; Blandino G; Nisticò P; Bagnato A; Rosanò L
Proc Natl Acad Sci U S A; 2018 Mar; 115(12):3132-3137. PubMed ID: 29439204
[TBL] [Abstract][Full Text] [Related]
11. STING agonism overcomes STAT3-mediated immunosuppression and adaptive resistance to PARP inhibition in ovarian cancer.
Ding L; Wang Q; Martincuks A; Kearns MJ; Jiang T; Lin Z; Cheng X; Qian C; Xie S; Kim HJ; Launonen IM; Färkkilä A; Roberts TM; Freeman GJ; Liu JF; Konstantinopoulos PA; Matulonis U; Yu H; Zhao JJ
J Immunother Cancer; 2023 Jan; 11(1):. PubMed ID: 36609487
[TBL] [Abstract][Full Text] [Related]
12. Activation of Wnt signaling promotes olaparib resistant ovarian cancer.
Yamamoto TM; McMellen A; Watson ZL; Aguilera J; Ferguson R; Nurmemmedov E; Thakar T; Moldovan GL; Kim H; Cittelly DM; Joglar AM; Brennecke EP; Wilson H; Behbakht K; Sikora MJ; Bitler BG
Mol Carcinog; 2019 Oct; 58(10):1770-1782. PubMed ID: 31219654
[TBL] [Abstract][Full Text] [Related]
13. HMGB3 promotes PARP inhibitor resistance through interacting with PARP1 in ovarian cancer.
Ma H; Qi G; Han F; Lu W; Peng J; Li R; Yan S; Yuan C; Kong B
Cell Death Dis; 2022 Mar; 13(3):263. PubMed ID: 35332131
[TBL] [Abstract][Full Text] [Related]
14. C/EBPβ promotes poly(ADP-ribose) polymerase inhibitor resistance by enhancing homologous recombination repair in high-grade serous ovarian cancer.
Tan J; Zheng X; Li M; Ye F; Song C; Xu C; Zhang X; Li W; Wang Y; Zeng S; Li H; Chen G; Huang X; Ma D; Liu D; Gao Q
Oncogene; 2021 Jun; 40(22):3845-3858. PubMed ID: 33966038
[TBL] [Abstract][Full Text] [Related]
15. ALDH1A1 Contributes to PARP Inhibitor Resistance via Enhancing DNA Repair in BRCA2
Liu L; Cai S; Han C; Banerjee A; Wu D; Cui T; Xie G; Zhang J; Zhang X; McLaughlin E; Yin M; Backes FJ; Chakravarti A; Zheng Y; Wang QE
Mol Cancer Ther; 2020 Jan; 19(1):199-210. PubMed ID: 31534014
[TBL] [Abstract][Full Text] [Related]
16. Blocking endothelin-1-receptor/β-catenin circuit sensitizes to chemotherapy in colorectal cancer.
Cianfrocca R; Rosanò L; Tocci P; Sestito R; Caprara V; Di Castro V; De Maria R; Bagnato A
Cell Death Differ; 2017 Oct; 24(10):1811-1820. PubMed ID: 28708138
[TBL] [Abstract][Full Text] [Related]
17. The interaction of β-arrestin1 with talin1 driven by endothelin A receptor as a feature of α5β1 integrin activation in high-grade serous ovarian cancer.
Masi I; Ottavi F; Del Rio D; Caprara V; Vastarelli C; Giannitelli SM; Fianco G; Mozetic P; Buttarelli M; Ferrandina G; Scambia G; Gallo D; Rainer A; Bagnato A; Spadaro F; Rosanò L
Cell Death Dis; 2023 Jan; 14(1):73. PubMed ID: 36717550
[TBL] [Abstract][Full Text] [Related]
18. The BET inhibitor INCB054329 reduces homologous recombination efficiency and augments PARP inhibitor activity in ovarian cancer.
Wilson AJ; Stubbs M; Liu P; Ruggeri B; Khabele D
Gynecol Oncol; 2018 Jun; 149(3):575-584. PubMed ID: 29567272
[TBL] [Abstract][Full Text] [Related]
19. Endothelin-1 drives invadopodia and interaction with mesothelial cells through ILK.
Masi I; Caprara V; Spadaro F; Chellini L; Sestito R; Zancla A; Rainer A; Bagnato A; Rosanò L
Cell Rep; 2021 Mar; 34(9):108800. PubMed ID: 33657382
[TBL] [Abstract][Full Text] [Related]
20. YAP and endothelin-1 signaling: an emerging alliance in cancer.
Tocci P; Blandino G; Bagnato A
J Exp Clin Cancer Res; 2021 Jan; 40(1):27. PubMed ID: 33422090
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
